Reversible slurred speech related to capecitabine and lapatinib combination in patients with breast cancer
Обратимая неясная речь, связанная с комбинацией капецитабина и лапатиниба у пациентов с раком молочной железы
2013-10-23
SCID: 54.1/jn3f62c5
Discuss with AI
advanced breast cancercapecitabinecapecitabine and lapatinib combinationlapatinibneurological adverse effectsreversible slurred speech
Figures from the paper
Abstract (AI)
Capecitabine plus lapatinib combination is an effective chemotherapy regimen in patients with advanced breast cancer. Neurological adverse effects secondary to this regimen were reported rarely in literature. A woman with breast cancer presented with complaints of slurred speech while using the capecitabine and lapatinib combination. Her major complaint was slurred speech. No other radiologic or laboratory disorders were detected in the patient. Slurred speech improved one week after the capecitabine and lapatinib combination was discontinued without any further intervention.
Key Findings
1
Capecitabine plus lapatinib combination can cause reversible slurred speech in a patient with breast cancer.
2
Neurological adverse effects from capecitabine and lapatinib are rare but can present as isolated speech disturbance.
3
Slurred speech resolved one week after discontinuation of the capecitabine and lapatinib regimen without additional intervention.
4
The patient's slurred speech occurred without other radiologic or laboratory abnormalities.
Research Object
Combination chemotherapy regimen of capecitabine and lapatinib used in patients with breast cancer
Research Subject
Reversible neurologic adverse effect manifesting as slurred speech associated with the capecitabine and lapatinib combination
Publication Details
Publication Date
2013-10-23
Journal
Publisher
ISSN
Access Type
Author Information
Download PDF
Subscribe to digest